EP3334747

AMGEN
Application Number
EP16757780A
Filing Date
Aug 12, 2016
Status
Granted And Under Opposition
Aug 25, 2023
Grant Date
Sep 27, 2023
External Links
Slate, Register

Biblio Summary

The patent EP3334747B1 was granted on Sep 27, 2023 by Amgen The patent is currently Granted And Under Opposition.

The table below shows 7 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBHJun 27, 2024ADMISSIBLE
HAMPTON KNOWLES LIMITEDJun 27, 2024ADMISSIBLE
HEMSATH, LARSJun 27, 2024ADMISSIBLE
MAIWALD GMBHJun 27, 2024ADMISSIBLE
WITHERS & ROGERS LLPJun 26, 2024ADMISSIBLE
MARGARET DIXON LIMITEDJun 7, 2024ADMISSIBLE
ROTH, CARLASep 28, 2023ADMISSIBLE

The table below shows the patents of Amgen that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP4209499Charged Depth Filtration Of Antigen-Binding ProteinsAug 7, 20241
EP3819007Dosing Regimen For Anti-Bcma AgentsJul 10, 20244
EP2637670Prevention Of Adverse Effects Caused By Cd3 Specific Binding DomainsMar 13, 20244